Search

Your search keyword '"Vioxx (Medication) -- Evaluation"' showing total 7 results
Start Over Descriptor "Vioxx (Medication) -- Evaluation" Topic celebrex (medication) -- evaluation
7 results on '"Vioxx (Medication) -- Evaluation"'

1. Safety of COX-2 Inhibitors

Author

Kubetin, Sally Koch

Subjects
Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation, COX-2 inhibitors -- Evaluation
Abstract

The cyclooxygenase-2 inhibitors are not superaspirins, but they are safer aspirins, Dr. David H. Corner said at the annual meeting of the Colorado chapter of the American College of Physicians--American [...]

Published
2000

2. COX-2 Inhibitors Are 'Safer Aspirins,' Not 'Superaspirins'

Author

JANCIN, BRUCE

Subjects
Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation, COX-2 inhibitors -- Evaluation
Abstract

COLORADO SPRINGS -- The cyclooxygenase-2 inhibitors are not "superaspirins," but they are "safer aspirins," Dr. David H. Collier said at the annual meeting of the Colorado chapter of the American [...]

Published
2000

3. COX-2 inhibitors face marketing challenges. (Newswire)

Subjects
Merck & Company Inc. -- Product information, Pharmaceutical industry -- Product information, Business, Health care industry, Celebrex (Medication) -- Evaluation, Vioxx (Medication) -- Evaluation
Abstract

A differentiation between the two leading COX-2 inhibitors, Celebrex and Vioxx, has been established after more than two years on the market, but the changes may lead to gastric distress [...]

Published
2002

4. Other ways to ease pain from arthritis

Author

Davis, Robert J.

Subjects
Arthritis -- Drug therapy, Glucosamine -- Evaluation, Chondroitin -- Evaluation, Business, Business, general, Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation
Published
2002

5. Vioxx beats Celebrex in acute pain?

Subjects
Merck & Company Inc. -- Evaluation, G.D. Searle and Co. -- Evaluation, Pharmaceutical industry -- Evaluation, Business, Pharmaceuticals and cosmetics industries, Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation
Abstract

A Merck & Co. 1999 study shows that dental patients receiving a 50 mg dose of Vioxx for relief of pain caused by surgery to remove two or more molars experienced faster pain relief onset and longer duration of action than patients who had received 200mg of Searle's Celebrex.

Published
1999

6. New Treatments for Osteoarthritis

Subjects
Vioxx (Medication) -- Evaluation, Celebrex (Medication) -- Evaluation, Feldene (Medication) -- Evaluation, Voltaren (Medication) -- Evaluation, Osteoarthritis -- Care and treatment, Drugs -- Evaluation
Abstract

CHANCES ARE you've heard about new medications for osteoarthritis, the degenerative joint disease that afflicts some 21 million Americans. The two drugs, Vioxx (rofecoxib), and Celebrex (celecoxib), have been getting [...]

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results